Tarveda Therapeutics to Present at the 2018 BIO CEO & Investor Conference
WATERTOWN, MA — February 5, 2018 – Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective cancer medicines, today announced that Drew Fromkin, President and Chief Executive Officer, will present at the 20th BIO CEO & Investor Conference, occurring February 12-13, 2018, at the New York Marriott Marquis, New York.
The presentation will take place at 3:00pm Eastern Time on Tuesday, February 13.
In the presentation, Mr. Fromkin will address the Company’s Pentarin miniature drug conjugate platform including PEN-221, which is currently in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) positive cancers including neuroendocrine and small cell lung cancers, and PEN-866, an HSP90 targeting conjugate, which is being developed for the treatment of patients with topoisomerase I inhibitor sensitive tumors including pancreatic cancer, small cell lung cancer and sarcoma.
Tarveda is developing Pentarins™, potent and selective miniature drug conjugates with high affinity for specific cell surface and intracellular targets in solid tumors. Pentarins are engineered to bind to their tumor cell targets, accumulate and provide sustained release of their potent therapeutic payloads deep into solid tumor tissue. Comprised of a targeting ligand conjugated to a potent cancer cell‑killing agent through a tuned chemical linker, Pentarins are designed to overcome the deficits of both larger antibody drug conjugates and small molecules that limit their therapeutic effectiveness against solid tumors. Together, the components of Tarveda’s Pentarins have distinct, yet synergistic, anticancer attributes: the small size of Pentarins allows for rapid and deep penetration into solid tumors, the ligand’s targeting ability allows for high affinity, selective binding and retention in tumor cells, and the chemical linker is tuned to optimize the release and accumulation of the potent, cell‑killing payload inside the cancer cells for efficacy. The design of the unique components together provides for the pharmacokinetics required for the critical level Pentarin concentrations in the tumor.
About Tarveda Therapeutics, Inc.
Tarveda Therapeutics, Inc. discovers and develops Pentarins™, a new class of potent and selective miniature drug conjugates with enhanced targeting capabilities and pharmacokinetics for the treatment of patients with a wide range of solid tumor cancers. Tarveda’s lead Pentarin clinical drug candidate, PEN‑221, targets the somatostatin receptor 2 (SSTR2) for treatment of patients with tumors that express SSTR2 including neuroendocrine, small cell lung and other cancers that express SSTR2. PEN-221 comprises a peptide, which is highly selective for SSTR2 conjugated to the potent cytotoxic DM1 through a tuned cleavable linker. Tarveda is also advancing its HSP90 drug conjugate platform with lead drug candidate PEN‑866, which is a miniature drug conjugate that selectively binds to the intracellular target, Heat Shock Protein 90 (HSP90), and is linked to the payload SN-38. Tarveda’s strategy includes developing its own proprietary Pentarins as well as applying the Pentarin platform to enhance the effectiveness of novel payloads of pharmaceutical collaborators. www.tarveda.com
George E. MacDougall
MacDougall Biomedical Communications
781 235 3060